Assignee
BRISTOL MYERS SQUIBB CO
US·3,333 granted patents·871 pending applications·76,811 citations·filing 1985–2025
Top patents by PatentIndex Score
4,204 records- 0199US9505839B2Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Nov 29, 2016·123 cites·16 claims
- 0299US6620821B2HMG-CoA reductase inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Sep 16, 2003·185 cites·18 claims
- 0399US6395767B2Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and methodBRISTOL MYERS SQUIBB CO·Filed 2001·Granted May 28, 2002·398 cites·24 claims
- 0499US6214345B1Lysosomal enzyme-cleavable antitumor drug conjugatesBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Apr 10, 2001·1.3k cites·258 claims
- 0599US6027655AApparatus and method for centrifugally separating blood and then forming a fibrin monomerBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Feb 22, 2000·167 cites·2 claims
- 0699US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0799US5712279AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Jan 27, 1998·319 cites·19 claims
- 0899US5612359ASubstituted biphenyl isoxazole sulfonamidesBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 18, 1997·533 cites·73 claims
- 0999US5508272ACompounds containing a fused bicycle ring and processes thereforBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Apr 16, 1996·218 cites·39 claims
- 1098US11866414B2Substituted heterocyclic compoundsBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Jan 9, 2024·11 cites·23 claims
- 1198US10662172B2Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted May 26, 2020·30 cites·121 claims
- 1298US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 1398US10377824B2Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 13, 2019·19 cites·30 claims
- 1498US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 1598US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 1698US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 1798US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 1898US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 1998US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 2098US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 2198US10266591B2Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 23, 2019·20 cites·37 claims
- 2298US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 2398US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 2498US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 2598US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 2698US7858739B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 28, 2010·84 cites·79 claims
- 2798US7741347B2Hepatitis C virus inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jun 22, 2010·52 cites·13 claims
- 2898US7572618B2Polynucleotides encoding novel PCSK9 variantsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 11, 2009·93 cites·22 claims
- 2998US7449479B2Hepatitis C virus inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 11, 2008·67 cites·16 claims
- 3098US7354924B2Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivativesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Apr 8, 2008·106 cites·6 claims
- 3198US7288638B2Fully human antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 30, 2007·245 cites·7 claims
- 3298US7238690B2Substituted heterocycle fused gamma-carbolinesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jul 3, 2007·127 cites·4 claims
- 3398US7153848B2Inhibitors of HCV replicationBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Dec 26, 2006·90 cites·32 claims
- 3498US6995174B2Hepatitis C virus inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Feb 7, 2006·194 cites·48 claims
- 3598US6849619B2Substituted pyridoindoles as serotonin agonists and antagonistsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Feb 1, 2005·119 cites·26 claims
- 3698US6774112B2Amino acid complexes of C-aryl glucosides for treatment of diabetes and methodBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Aug 10, 2004·229 cites·19 claims
- 3798US6727271B2Substituted acid derivatives useful as antidiabetic and antiobesity agents and methodBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Apr 27, 2004·92 cites·19 claims
- 3898US6670357B2Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Dec 30, 2003·137 cites·24 claims
- 3998US6623940B1Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 23, 2003·133 cites·17 claims
- 4098US6596746B1Cyclic protein tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Jul 22, 2003·257 cites·49 claims
- 4198US6548529B1Heterocyclic containing biphenyl aP2 inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Apr 15, 2003·273 cites·27 claims
- 4298US6515117B2C-aryl glucoside SGLT2 inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 4, 2003·372 cites·17 claims
- 4398US6476034B2Antiviral azaindole derivativesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 5, 2002·103 cites·24 claims
- 4498US6414002B1Substituted acid derivatives useful as antidiabetic and antiobesity agents and methodBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Jul 2, 2002·204 cites·30 claims
- 4598US6414126B1C-aryl glucoside SGLT2 inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Jul 2, 2002·380 cites·30 claims
- 4698USD443060SBone plateBRISTOL MYERS SQUIBB CO·Filed 2000·Granted May 29, 2001·189 cites·1 claims
- 4798US6132992AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 17, 2000·387 cites·54 claims
- 4898US6043265AIsoxazolyl endothelin antagonistsBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Mar 28, 2000·402 cites·55 claims
- 4998US5885983AInhibitors of microsomal triglyceride transfer protein and methodBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·176 cites·15 claims
- 5098US5844095ACTLA4 Ig fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 1, 1998·417 cites·2 claims
Showing the top 50 of 4,204 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BRISTOL MYERS SQUIBB CO files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →